When Reflux Needs a Scope

Why most reflux gets treated before it gets looked at

Because the treatment is safer, cheaper, and faster than the test. For classic heartburn and regurgitation with none of the alarm features below, the American College of Gastroenterology's pathway starts with an eight-week trial of a once-daily proton pump inhibitor, and reserves upper endoscopy for the people that trial does not help, for those with alarm symptoms, and for those whose reflux history puts them at risk for Barrett's esophagus 1Ref 1Katz PO, Dunbar KB, Schnoll-Sussman FH, Greer KB, Yadlapati R, Spechler SJ (2022).ACG Clinical Guideline for the Diagnosis and Management of Gastroesophageal Reflux Disease.The empiric-PPI-first pathway: an eight-week once-daily PPI trial for classic heartburn and regurgitation without alarm features, and upper endoscopy — performed off the PPI — for trial non-responders, for alarm symptoms, and for those at risk of Barrett's esophagus..

That order surprises people. It can feel as though a camera is the thorough answer and a pill the lazy one. The logic runs the other way. Endoscopy is very good at finding structural damage — an inflamed esophagus, a narrowing, a hernia, a precancerous change — and reflux, most of the time, produces none of those. A scope that finds nothing has not ruled reflux out, because most reflux leaves no mark. It has spent a morning, a sedation, and a bill to say what the eight weeks would have said.

Reflux and reflux disease are not the same word. Occasional reflux — stomach contents washing back into the esophagus — is something nearly everyone does, and NIDDK calls that plain GER. It becomes GERD when it is persistent, symptomatic often enough to matter, or causing complications 2Ref 2National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) (2020).Definition & Facts for GER & GERD.The definitional distinction between GER (occasional reflux of stomach contents into the esophagus) and GERD (reflux that is persistent, symptomatic, or complication-causing).. That distinction does quiet work in every decision on this page: the question is never "is acid coming up?" but "is it coming up in a way that has changed something, or that might."

The machinery is unglamorous. The lower esophageal sphincter — the muscular ring meant to stay shut between swallows — relaxes when it should not, or a hiatal hernia lets part of the stomach sit above the diaphragm, and the acid follows the path it is given. Heartburn and regurgitation are what that feels like 3Ref 3National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) (2020).Symptoms & Causes of GER & GERD.That heartburn and regurgitation are the characteristic symptoms of GERD, and that the mechanism involves a weak or inappropriately relaxing lower esophageal sphincter and hiatal hernia.. What gerd actually is, mechanically, is worth reading once; it explains why so much of the treatment is about pressure and timing rather than acid alone.

What counts as an alarm feature?

An alarm feature is a symptom that shifts the odds enough that the trial gets skipped and the look happens first. The ACG and CAG dyspepsia guideline names the short list plainly: unintended weight loss, gastrointestinal bleeding, and difficulty swallowing. Any one of them moves a person toward upper endoscopy rather than toward an empiric course of acid suppression 4Ref 4Moayyedi P, Lacy BE, Andrews CN, Enns RA, Howden CW, Vakil N (2017).ACG and CAG Clinical Guideline: Management of Dyspepsia.The alarm-feature list (unintended weight loss, gastrointestinal bleeding, difficulty swallowing) and the age threshold: upper endoscopy for dyspepsia at 60 or over or with alarm features, and H. pylori test-and-treat or empiric acid suppression under 60 without alarm features..

An alarm feature does not become less alarming because a harmless explanation is more common. It usually is more common. That is not the point. The list is short precisely because each item is a symptom the serious diagnoses produce and the ordinary ones mostly do not, and the whole value of the list collapses if it is argued away one case at a time.

• Difficulty swallowing. Food that hesitates, sticks, or has to be washed down. This is the one people explain away longest, usually by eating slowly and cutting food smaller — which works well enough to hide the trend for months. Difficulty swallowing has a long differential of its own; the relevant fact here is that it belongs in front of a clinician rather than a strategy.
• Bleeding. Vomit with blood in it, or vomit that looks like coffee grounds; stool that is black and tarry. Blood from an upper source is digested on the way through, which is what turns it dark — so the absence of anything red is not the absence of blood.
• Unintended weight loss. Weight that leaves without being asked to, while the reflux is going on.

A parallel list runs downstream in the gut and decides who gets a colonoscopy instead. The GI alarm features overlap with these but are not identical, and the two lists route to different procedures — which is why "I have an alarm symptom" starts a conversation about where to look rather than an order for a particular test.

The eight-week trial, and what it means when it does not work

Eight weeks is not an arbitrary wait. It is long enough for a genuinely acid-driven problem to declare itself: an inflamed esophagus heals under suppression, and symptoms driven by acid recede. The ACG pathway sets that trial at once-daily dosing for classic symptoms, and treats failure of the trial as an indication to look — a non-responder has earned an endoscopy 1Ref 1Katz PO, Dunbar KB, Schnoll-Sussman FH, Greer KB, Yadlapati R, Spechler SJ (2022).ACG Clinical Guideline for the Diagnosis and Management of Gastroesophageal Reflux Disease.The empiric-PPI-first pathway: an eight-week once-daily PPI trial for classic heartburn and regurgitation without alarm features, and upper endoscopy — performed off the PPI — for trial non-responders, for alarm symptoms, and for those at risk of Barrett's esophagus..

Failure means something specific, and it is worth being precise about what it does and does not imply. It does not mean the drug was too weak. It means the hypothesis was wrong or incomplete. Several very different things live behind an unhelpful trial: the symptom was never acid; the symptom was acid plus something structural that suppression cannot fix; the esophagus is hypersensitive rather than damaged; or the medicine was never taken the way the trial assumed.

That last one is not a scolding — it is the most common confounder in the pathway, and it is mechanical rather than moral. These medicines are not antacids. They act on the acid pumps that are switched on, so when a dose lands relative to eating changes how much of it does anything at all. A course run on a different schedule from the one the guideline describes is not a trial that failed; it is a trial that was never quite run. Worth asking the prescriber how the eight weeks were meant to be taken, and whether they were, before a scope gets booked to answer a question the trial never asked.

What a real failure earns is a look, not a stronger prescription. That is the fork the pathway is built around: eight fair weeks, and then the road splits — better, and you have your answer; unchanged, and the next step is information rather than escalation.

Why the scope is done off the medicine

Because acid suppression erases the evidence. The ACG pathway specifies that when endoscopy is done for reflux, it is done off the PPI 1Ref 1Katz PO, Dunbar KB, Schnoll-Sussman FH, Greer KB, Yadlapati R, Spechler SJ (2022).ACG Clinical Guideline for the Diagnosis and Management of Gastroesophageal Reflux Disease.The empiric-PPI-first pathway: an eight-week once-daily PPI trial for classic heartburn and regurgitation without alarm features, and upper endoscopy — performed off the PPI — for trial non-responders, for alarm symptoms, and for those at risk of Barrett's esophagus.. Someone who has been on suppression for months and is then scoped may well have a normal-looking esophagus — not because nothing was ever wrong, but because the drug healed the very thing the camera came to see.

This matters more than it sounds. The findings that change a plan — erosive inflammation and its grade, a narrowing, the salmon-colored tongue of lining that raises the question of Barrett's — are exactly the findings treatment softens or resolves. Scope someone on a working PPI and the report says "normal," which is the least useful sentence in the encounter: it neither confirms nor excludes, and it gets read as "nothing is wrong" by almost everyone, sometimes including the person who ordered it.

So the sequence has a shape, and it is easy to get wrong by being sensible. Stop the medicine, wait, then look. The length of that wait is set by the clinician arranging the procedure and is not the same for everyone, which is why the instruction properly arrives from the endoscopy unit rather than from an article. Worth knowing in advance: the reflux will return during the window, and that is expected rather than a sign the plan is failing. The symptoms coming back is, in a sense, the point.

The exception is the person being scoped for an alarm feature. There the question is not "how bad is the reflux" but "what else is in there," and bleeding or swallowing trouble is not a reason to arrange a washout first.

When chronic reflux is itself the reason to look

Some endoscopies are not about the symptoms at all. They are about the years. Barrett's esophagus is a change in the lining of the lower esophagus — a complication of long-standing GERD, and the only known precursor to esophageal adenocarcinoma. The ACG's Barrett's guideline suggests a single screening endoscopy for people with chronic reflux who also carry three or more additional risk factors 5Ref 5Shaheen NJ, Falk GW, Iyer PG, Souza RF, Yadlapati RH, Sauer BG, Wani S (2022).Diagnosis and Management of Barrett's Esophagus: An Updated ACG Guideline.That Barrett's esophagus is a complication of chronic GERD and the only known precursor to esophageal adenocarcinoma; the indication for a single screening endoscopy in chronic GERD plus three or more additional risk factors, and the risk factors that count; and that PPI therapy is recommended once Barrett's is diagnosed..

Barrett's esophagus is the reason the word "chronic" keeps appearing on this page. The risk factors the guideline stacks alongside chronic GERD are male sex, age over 50, white race, tobacco smoking, obesity, and a first-degree relative with Barrett's or esophageal adenocarcinoma 5Ref 5Shaheen NJ, Falk GW, Iyer PG, Souza RF, Yadlapati RH, Sauer BG, Wani S (2022).Diagnosis and Management of Barrett's Esophagus: An Updated ACG Guideline.That Barrett's esophagus is a complication of chronic GERD and the only known precursor to esophageal adenocarcinoma; the indication for a single screening endoscopy in chronic GERD plus three or more additional risk factors, and the risk factors that count; and that PPI therapy is recommended once Barrett's is diagnosed.. Three or more of those, plus years of reflux, and the calculus changes: the scope is no longer hunting for the cause of this month's heartburn. It is looking for a change that has no symptoms of its own.

That clause is the whole argument. Barrett's does not hurt. It does not add a symptom to the reflux and it does not announce itself by making the burn worse. For some people the reflux even quiets as the lining changes. This is precisely why the indication is built out of risk factors and duration rather than out of how bad the week has been. There is nothing to feel, so there is nothing to wait for, so the trigger has to be arithmetic instead.

The word "single" does work too. It is a screening endoscopy, not a standing appointment: for most people with chronic reflux and enough risk factors, one look answers the question. If it does find Barrett's, two things follow — acid suppression is recommended for people who have it 5Ref 5Shaheen NJ, Falk GW, Iyer PG, Souza RF, Yadlapati RH, Sauer BG, Wani S (2022).Diagnosis and Management of Barrett's Esophagus: An Updated ACG Guideline.That Barrett's esophagus is a complication of chronic GERD and the only known precursor to esophageal adenocarcinoma; the indication for a single screening endoscopy in chronic GERD plus three or more additional risk factors, and the risk factors that count; and that PPI therapy is recommended once Barrett's is diagnosed., and the person moves into barrett's surveillance, a schedule of repeat looks whose intervals depend on what the biopsies showed and belong in a conversation with the gastroenterologist who took them.

What a scope can and cannot resolve is worth knowing beforehand. An endoscopy for gerd is a look at the lining and a set of biopsies. It is not a measurement of how much acid is coming up, and those two questions have different tests.

Does age change the threshold?

It does, but for a slightly different symptom than the one most people mean. The ACG and CAG dyspepsia guideline sets the pivot at 60: a person aged 60 or over with dyspepsia gets an upper endoscopy, while a person under 60 without alarm features is managed with H. pylori test-and-treat, empiric acid suppression, or both 4Ref 4Moayyedi P, Lacy BE, Andrews CN, Enns RA, Howden CW, Vakil N (2017).ACG and CAG Clinical Guideline: Management of Dyspepsia.The alarm-feature list (unintended weight loss, gastrointestinal bleeding, difficulty swallowing) and the age threshold: upper endoscopy for dyspepsia at 60 or over or with alarm features, and H. pylori test-and-treat or empiric acid suppression under 60 without alarm features..

Dyspepsia is not heartburn, and the distinction is not pedantry. Dyspepsia means discomfort centered in the upper abdomen — a gnawing, an early fullness, a pain that lives above the navel rather than behind the breastbone. Classic reflux is the burn that climbs and the sour rise into the throat. They overlap in real people constantly, and plenty of people have both, but the guideline governing each is a different document, and the age-60 line belongs to the dyspepsia one. A 62-year-old whose only complaint is textbook heartburn is not automatically on the endoscopy side of that line.

What the line is really doing is arithmetic on background risk. The serious findings an upper endoscopy exists to catch get likelier with each decade, and at some point the yield of looking crosses the cost of looking. Sixty is where that guideline drew it. The number is a threshold rather than a wall — one input into a decision that also weighs how long the symptom has run, what else is in the history, and what a previous trial did.

Under 60 and without an alarm feature, the pathway is still not the camera 4Ref 4Moayyedi P, Lacy BE, Andrews CN, Enns RA, Howden CW, Vakil N (2017).ACG and CAG Clinical Guideline: Management of Dyspepsia.The alarm-feature list (unintended weight loss, gastrointestinal bleeding, difficulty swallowing) and the age threshold: upper endoscopy for dyspepsia at 60 or over or with alarm features, and H. pylori test-and-treat or empiric acid suppression under 60 without alarm features.. That is a real recommendation rather than a delay, and it is worth hearing as one: an empiric strategy is the guideline's answer, not the consolation prize handed out when insurance says no.

Cough, hoarseness, and "silent reflux" — the hardest call

This is where the pathway gets genuinely uncertain, and the honest answer is that a scope often will not settle it. The AGA's clinical practice update on extraesophageal reflux is unusually candid about the problem: there is no single confirmatory test for reflux as the cause of a chronic cough, a hoarse voice, or a raw throat; the diagnosis rests on a global clinical impression; and an empiric PPI trial is low-yield when the typical GERD symptoms are absent 6Ref 6Chen JW, Vela MF, Peterson KA, Carlson DA (2023).AGA Clinical Practice Update on the Diagnosis and Management of Extraesophageal Gastroesophageal Reflux Disease: Expert Review.That suspected extraesophageal reflux (chronic cough, hoarseness, laryngitis) has no single confirmatory test, that diagnosis rests on global clinical impression, and that empiric PPI therapy is low-yield when typical GERD symptoms are absent..

Read that last clause carefully, because it inverts what usually happens. The common path for a months-long cough is a course of acid suppression on the theory that silent reflux is behind it. The AGA's point is that when a person has no heartburn and no regurgitation — when the reflux is silent in the fullest sense — that trial is least likely to help, and a negative result does not exclude reflux either. It produces a more expensive version of the uncertainty it started with.

What follows is not nothing. It is just slower. The throat and larynx have several plausible tenants and reflux is only one; a sensible workup treats it as one hypothesis among several rather than the default, and usually involves more than one specialty. Endoscopy has a role here, but a modest one — better at excluding a structural problem than at proving acid is the cough's author.

A cough that has outlasted a course of acid suppression is not evidence that something rare and terrible is happening. It is more often evidence that the first hypothesis was the wrong one, which is an ordinary way for a diagnosis to go, and a reason to keep the follow-up appointment rather than to escalate the search alone.

The decision in one view

The pathway is easier to hold as a table than as a paragraph. Each row is a situation, and what it points to is the guideline's next move — not a promise about what will be found. The rows are not mutually exclusive, and they are not ranked equally: an alarm feature outranks everything below it, and a single one is enough on its own.

The row that catches most people is the third, and it catches them from the wrong direction: a failed trial gets read as a reason to double the medicine and run the experiment again. The pathway reads it as the moment the question changed — from "how do we treat this reflux" to "is this reflux." Those are different questions, and only one of them has a camera as the answer.